Research theme for competitive and other funds (1)：
2016 - 2019 Molecular mechanism of sarcopenia in cancer patients
Papers (31)：
Eri Takada, Nobuhiko Nakamura, Yuto Kaneda, Kenji Fukuno, Shin Lee, Kei Fujita, Tetsuji Morishita, Yoshikazu Ikoma, Takuro Matsumoto, Hiroshi Nakamura, et al. Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine. Hematology Reports. 2024
Yuto Kaneda, Nobuhiro Kanemura, Nobuhiko Nakamura, Yoshikazu Ikoma, Kimihiro Yamaguchi, Eri Takada, Yuhei Shibata, Shin Lee, Kei Fujita, Tetsuji Morishita, et al. The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma. 2024
Yoshikazu Ikoma, Nobuhiko Nakamura, Junichi Kitagawa, Takao Miwa, Eri Takada, Takuro Matsumoto, Yuhei Shibata, Hiroshi Nakamura, Nobuhiro Kanemura, Senji Kasahara, et al. A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma. Hematological Oncology. 2024
Yasuhito Nannya, Magnus Tobiasson, Shinya Sato, Elsa Bernard, Shigeki Ohtake, June Takeda, Maria Creignou, Lanying Zhao, Manabu Kusakabe, Yuhei Shibata, et al. Post-azacitidine clone size predicts outcome of patients with myelodysplastic syndromes and related myeloid neoplasms. Blood advances. 2023
Satsuki Murakami, Masaki Ri, Masato Ito, Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Yuichiro Inagaki, Junya Kuroda, Makoto Yoshimitsu, Akinao Okamoto, et al. Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma. International journal of hematology. 2022. 116. 4. 563-569
